Construction of a lentivirus vector for Trail gene in rats

doi:10.3969/j.issn.2095-4344.2014.02.017

Abstract

Abstract:

BACKGROUND: Adenovirus, expressing within a limited period, can limit the expression time and amount of target genes that is not conducive to ongoing experiments. Here, we select adenovirus as vectors for genetic recombination with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Trail) gene fragment.
OBJECTIVE: To explore the construction of recombinant lentiviral vector carrying Trail in rats
METHODS: The Trail gene was obtained: according to GenBank in rat Trail gene sequence (NM_145681.1), we designed the gene specific primers of Trail-Age I-F and Trail-AgeI-R, and used AgeI as enzyme cutting site. PCR was applied to amplify Trail gene from rat cDNA Library and construct recombinant plasmids after cutting Trail gene to be cloned into expression vector GV218 by AgeI. Recombinant plasmids were transfected into 293T cells by Lipofeetamine2000 encapsulated recombinant plasmid and auxiliary packaging carrier. The Trail protein of lentiviral plasmids was expressed. Following virus collection, we identified virus titer and extracted protein from cells to detect Trail expression by western blot assay.
RESULTS AND CONCLUSION: Screened positive Escherichia coli DH5a competent cells were sequenced with 861 bp, which was consistent with Trail nucleotide sequence in GenBank. After transfection 2 days, virus liquid was collected and confirmed as recombinant plasmid including Trail gene by PCR and Trail proteins expressed in 293T cells by western blot assay. Hole dilution method and real-time fluorescent quantitative PCR determination showed that the virus titer was 2×109 TU/mL. In this study, recombinant lentiviral vector carrying Trail is successfully constructed by homologous recombination in Escherichia coli.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: TNF-related apoptosis-inducing ligand, genes, plasmids, polymerase chain reaction, blotting, western

CLC Number:

R318

Zhang Hai, Jiang Zheng-fang, Liu Yang, Zhang Bo, Wu Gui-qiang, Zeng Ling-yong. Construction of a lentivirus vector for Trail gene in rats[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(2): 265-270.

Figures/Tables 4

References

[1] Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013; 525(2):162-169.

[2] Boye SE, Boye SL, Lewin AS, et al. A comprehensive review of retinal gene therapy. Mol Ther. 2013;21(3):509-519.

[3] Davanzo R, Zauli G, Monasta L, et al. Human colostrum and breast milk contain high levels of TNF-related apoptosis-inducing ligand (TRAIL). J Hum Lact. 2013; 29(1): 23-25.

[4] Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002; 7(5): 449-459.

[5] Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010; 29(34): 4752- 4765.

[6] Pietersen AM, van der Eb MM, Rademaker HJ, et al. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene.Gene Ther. 1999; 6(5):882-892.

[7] Shi J, Zheng D, Liu Y, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumorxenografts in nude mice. Cancer Res. 2005; 65(5):1687-1692.

[8] Chen C, Akerstrom V, Baus J, et al. Comparative analysis of the transduction efficiency of five adeno associated virus serotypes and VSV-G pseudotype lentiviral vector in lung cancer cells. Virol J. 2013; 10:86.

[9] Yan F, Zheng Y, Huang L. Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma. Oncol Lett. 2013; 5(1):348-354.

[10] Zhang Y, Qu ZH, Cui M, et al. Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biol Ther. 2009; 8(5):466-473.

[11] Sun W, Jiang Z, Xiang TX, et al. Anti-tumor effect of eukaryotic expressing plasmid containing soluble tumor necrotic factor-related apoptosis inducing ligand combined with human angiostatin Kringle (1 - 3) genes on human gastric cancer xenografts in nude mice. Zhonghua Yi Xue Za Zhi. 2009; 89(12):841-845.

[12] Rasul A, Yu B, Zhong L, et al. Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. Oncol Rep. 2012; 27(5):1481-1487.

[13] Zheng Y, Chen H, Zeng X, et al. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system ofTRAIL and endostatin for cervical cancer gene therapy. Nanoscale Res Lett. 2013; 8(1):161.

[14] Qiu B, Ji M, Song X, et al. Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer. Nanoscale Res Lett. 2012; 7(1): 666.

[15] Moniri MR, Sun XY, Rayat J, et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 2012; 19(9):652-658.

[16] Mohr A, Albarenque SM, Deedigan L, et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells. 2010 ;28(11):2109- 120.

[17] Xia P, Zhu J, Zhu G. Escherichia coli Nissle 1917 as safe vehicles for intestinal immune targeted therapy--a review. Wei Sheng Wu Xue Bao. 2013;53(6):538-544.

[18] Cronin M, Stanton RM, Francis KP, et al. Bacterial vectors for imaging and cancer gene therapy: a review. Cancer Gene Ther. 2012;19(11):731-740.

[19] Bhatia S, Menezes ME, Das SK, et al. Innovative approaches for enhancing cancer gene therapy. Discov Med. 2013; 15(84): 309-317.

[20] Prinz-Hadad H, Mizrachi T, Irony-Tur-Sinai M, et al. Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14•TRAIL. J Neuroinflammation. 2013;10:36.

[21] Chiu TL, Wang MJ, Su CC. The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model. J Biomed Sci. 2012;19:45.

[22] Balyasnikova IV, Ferguson SD, Han Y, et al. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett. 2011; 310(2): 148-159.

[23] El-Aneed A. An overview of current delivery systems in cancer gene therapy. Journal of Controlled Release. 2004; 94(1):1-14.

[24] Mancheño-Corvo P, Martín-Duque P. Viral gene therapy. Clin Transl Oncol. 2006;8(12):858-867.

[25] Schabowsky RH, Sharma RK, Madireddi S, et al. ProtEx technology for the generation of novel therapeutic cancer vaccines. Exp Mol Pathol. 2009; 86(3):198-207.

[26] Schweizer M, Merten OW. Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther. 2010; 10(6):474-486.

[27] Segura MM, Mangion M, Gaillet B, et al. New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther. 2013;13(7):987-1011.

[28] Fu XR, Zhang XD, Zhang C, et al. Construction of a lentiviral vector carrying TRAIL gene and its infection efficiency to lymphoma cells in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(4):900-905.